Perspectives by the Leerink Center for Pharmacoeconomics

The Leerink Center for Pharmacoeconomics
  • 5.0 (3)
  • INVESTING
  • UPDATED MONTHLY

Welcome to Perspectives, a signature podcast series from the Leerink Center for Pharmacoeconomics. Hosted by Dr. Mel Whittington, a health economist and Head of the Center for Pharmacoeconomics, we will be hearing from individuals across the industry to better understand and appreciate the societal impact of healthcare innovations.

  1. Specialty Drug Coverage Predictions with James Chambers, PhD, MPharm, Professor of Medicine, CEVR, Tufts Medical Center

    FEB 2

    Specialty Drug Coverage Predictions with James Chambers, PhD, MPharm, Professor of Medicine, CEVR, Tufts Medical Center

    Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, interviews James Chambers, PhD, MPharm, Professor of Medicine in the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, to dig into specialty drug coverage and what it might look like in 2026.

    36 min
  2. The National Pharmaceutical Council President and CEO & Former Trump Drug Pricing Advisor, John O'Brien, PharmD, MPH

    JAN 8

    The National Pharmaceutical Council President and CEO & Former Trump Drug Pricing Advisor, John O'Brien, PharmD, MPH

    Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, talks with John M. O'Brien, PharmD, MPH, President and CEO of the National Pharmaceutical Council & Former Trump Drug Pricing Advisor, to tackle some big questions like if it is possible to reward innovation without busting budgets and how to get to a sustainable, innovation-friendly, patient-centered drug pricing system. Additional resources: Subscribe to NPC’s Newsletter https://www.npcnow.org/subscribe-updates IRA Impact on Pharmaceutical Investment: Insights From Investor Interviews (Health Affairs Scholar) https://academic.oup.com/healthaffairsscholar/article/3/9/qxaf156/8223954 How Time Is Accounted For When Modeling Pharmaceutical Impacts: Investment vs Assessment Perspectives (Health Affairs Scholar) https://academic.oup.com/healthaffairsscholar/article/3/9/qxaf169/8244606 The IRA and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials (Therapeutic Innovation & Regulatory Science) https://link.springer.com/article/10.1007/s43441-025-00774-2 Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act (Therapeutic Innovation & Regulatory Science) https://link.springer.com/article/10.1007/s43441-024-00706-6 Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications (American Journal of Managed Care) https://www.ajmc.com/view/unintended-consequences-of-the-inflation-reduction-act-clinical-development-toward-subsequent-indications The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs (Value in Health) https://www.valueinhealthjournal.com/article/S1098-3015(25)02527-6/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301525025276%3Fshowall%3Dtrue Follow John O’Brien on LinkedIn https://www.linkedin.com/in/drjmob/

    38 min
  3. David Hong, MD, Steve Potts, PhD, MBA, and Vivek Subbiah, MD talk Pan-Tumor Approvals in a Post-IRA World

    12/02/2025

    David Hong, MD, Steve Potts, PhD, MBA, and Vivek Subbiah, MD talk Pan-Tumor Approvals in a Post-IRA World

    Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, talks with Vivek Subbiah, MD, David Hong, MD, and Steve Potts, PhD, MBA to discuss if pan-tumor approval strategies offer a path forward for broader, faster adoption across larger patient populations. Given the slow adoption curves typical of new therapeutics and the potential for government price negotiation as early as nine years after market entry, the experts hash out if pan-tumor approval is a potential development and commercialization pathway to ramp up clinical adoption and sales early on. They discuss the challenges, data requirements, and opportunities of this relatively new development path. Dr. Hong is the Deputy Chair of the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center. Dr. Steve Potts is the CEO and Co-Founder of a Stealth Cancer Biotech. Dr. Subbiah is the Chief of Early Phase Drug Development at the Sarah Cannon Research Institute. All bring firsthand experience – wins and battle scars - with pan-tumor approvals.

    42 min
  4. Head of the Leerink Center for Pharmacoeconomics, Melanie Whittington, PhD

    11/03/2025

    Head of the Leerink Center for Pharmacoeconomics, Melanie Whittington, PhD

    Diane Vieira, Head of Marketing & Communications at Leerink Partners, interviews Melanie Whittington, PhD, Head of the Leerink Center of Pharmacoeconomics (CPE), to discuss the one-year anniversary of CPE and everything they thought they knew but actually didn’t.

  5. Steve Potts, PhD, MBA, CEO and Co-Founder, Stealth Cancer Biotech

    10/06/2025

    Steve Potts, PhD, MBA, CEO and Co-Founder, Stealth Cancer Biotech

    Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, interviews Steve Potts, PhD, MBA, CEO and Co-Founder, Stealth Cancer Biotech, to discuss the impact of the Inflation Reduction Act on cancer drug development and a middle ground between a market-based approach and a government-based approach to drug pricing.

  6. The IP Policy Institute’s Joshua Kresh and Emily Michiko Morris

    09/08/2025

    The IP Policy Institute’s Joshua Kresh and Emily Michiko Morris

    Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, interviews Joshua Kresh and Emily Michiko Morris from The IP Policy Institute at the University of Akron School of Law to discuss the critical importance of protecting intellectual property for the biopharmaceutical innovation ecosystem and their recent research around evergreening and patent thickets.

  7. Director of Access and Policy Research at Johnson & Johnson, Ulrich Neumann, MBA, MSc, MA

    08/13/2025

    Director of Access and Policy Research at Johnson & Johnson, Ulrich Neumann, MBA, MSc, MA

    Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, interviews Ulrich Neumann, MBA, MSc, MA, Director of Access and Policy Research at Johnson & Johnson, to discuss the motivation behind the recent launch of the J&J Center for U.S. Healthcare Policy Research, the interconnectedness and importance of the various players within the biopharmaceutical R&D ecosystem, and the private capital that is required to develop new drugs. Resources mentioned in this episode: https://policyresearch.jnj.com https://jnjinnovation.com/home https://www.nature.com/articles/d41573-024-00131-2 https://www.ispor.org/docs/default-source/intl2024/j-j-access-policy-research---ispor-2024---pharma-r-d-ecosystem-investment137860-pdf.pdf?sfvrsn=d28181d4_0 https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2405407

  8. Head of Patient Engagement and Patient-Centered Innovation, Raven, RA Capital's healthcare incubator, Gunnar Esiason, MBA, MPH

    07/14/2025

    Head of Patient Engagement and Patient-Centered Innovation, Raven, RA Capital's healthcare incubator, Gunnar Esiason, MBA, MPH

    Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, talks with Gunnar Esiason, Head of Patient Engagement and Patient-Centered Innovation at Raven, RA Capital's healthcare incubator, where they discuss the far-reaching impact of biopharmaceutical innovation, as well as the time, effort, and capital that goes into developing new treatments.

See All (15)

Trailer

Ratings & Reviews

5
out of 5
3 Ratings

About

Welcome to Perspectives, a signature podcast series from the Leerink Center for Pharmacoeconomics. Hosted by Dr. Mel Whittington, a health economist and Head of the Center for Pharmacoeconomics, we will be hearing from individuals across the industry to better understand and appreciate the societal impact of healthcare innovations.

Information

  • Creator
    The Leerink Center for Pharmacoeconomics
  • Years Active
    2025 - 2026
  • Episodes
    15
  • Rating
    Clean
  • Copyright
    © 2026 Perspectives by the Leerink Center for Pharmacoeconomics The Leerink Center for Pharmacoeconomics

You Might Also Like